Your session is about to expire
← Back to Search
Other
ALTO-100 in MDD and/or PTSD
Phase 2
Waitlist Available
Research Sponsored by Alto Neuroscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 5 times over 8 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to study ALTO-100, a treatment, by collecting data on how it affects the body. Researchers are looking at biological markers to understand its effects. The study does not specify a particular patient group.
Eligible Conditions
- Post-Traumatic Stress Disorder
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured 5 times over 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 5 times over 8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100
Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-100
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ALTO-100Experimental Treatment1 Intervention
ALTO-100 PO tablet, daily dosing 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTO-100 PO tablet
2021
Completed Phase 2
~250
Find a Location
Who is running the clinical trial?
Alto NeuroscienceLead Sponsor
10 Previous Clinical Trials
1,093 Total Patients Enrolled